Suppr超能文献

器官共享联合网络科学肾脏移植登记处。

The UNOS Scientific Renal Transplant Registry.

作者信息

Cecka J M, Terasaki P I

机构信息

UCLA Tissue Typing Laboratory.

出版信息

Clin Transpl. 1993:1-18.

PMID:7918142
Abstract
  1. The one-, 3-, and projected 10-year graft survival rates for the 35,741 first cadaveric transplants reported to the UNOS Registry were 81%, 69%, and 40%, respectively. The corresponding results of transplantations from parent donors were 90%, 81%, and 54%, and from HLA-identical siblings, 95%, 90%, and 74%. 2. Graft survival rates have improved significantly since the Registry began collecting data in October 1987. Between 1988 and 1991, survival of first-cadaver transplants rose from 77% to 84% (p < 0.001), while that of second transplants increased from 69% to 80% (p < 0.001). Some of the increase in graft survival rates was attributed to a 4-5% improvement in patient survival over the same interval. 3. Graft survival also improved among recipients of living-donor transplants. Overall survival increased from 88% in 1988 to 93% in 1991 (p < 0.003), although the results for 1992 suggest 92% may be a better expectation. The approximately 4% rise was distributed among recipients from each of the major donor relationships: HLA-identical siblings (3%); one-haplotype-matched siblings (8%); and parents (4%). Patient survival improved by one to 3%. 4. Transplants between spouses and those between distant relatives or other unrelated donors yielded excellent results. Graft survival rates at one and 3 years for 284 spousal-donor transplants were 92% and 85%, respectively. The corresponding results for 533 patients transplanted from distant relatives or other living donors were 91% and 84%. In each case, the results were higher than those for transplants from parents to their children (though the difference was not statistically significant). 5. Antilymphocyte antibodies (ALG/ATG/OKT3) given prophylactically resulted in up to a 4% improvement in graft survival rates for recipients of first-cadaver transplants. Patients who received a kidney mismatched at one or 2 HLA antigens had a 2-10% higher graft survival rate each year than those mismatched at 5 or 6 antigens. 6. HLA matching resulted in higher graft survival rates for Whites, Blacks, and Asians. Among Whites, where there was a large number of well-matched transplants, 3-year graft survival was 84% with no mismatches, and 75%, 71%, and 67%, with one or 2, 3 or 4, and 5 or 6 mismatches, respectively. Each decrease in 3-year survival was significant (p < 0.001). Among Blacks and Asians, the rankings showed a similar trend although the number of well-matched patients was small in each race.(ABSTRACT TRUNCATED AT 400 WORDS)
摘要
  1. 向器官共享联合网络(UNOS)登记处报告的35741例首例尸体肾移植的1年、3年及预计10年移植肾存活率分别为81%、69%和40%。来自亲属供体移植的相应结果分别为90%、81%和54%,来自人类白细胞抗原(HLA)完全相同同胞供体的移植结果分别为95%、90%和74%。2. 自登记处在1987年10月开始收集数据以来,移植肾存活率有了显著提高。在1988年至1991年期间,首例尸体肾移植的存活率从77%升至84%(p<0.001),而再次移植的存活率则从69%增至80%(p<0.001)。移植肾存活率的部分提高归因于同一时期患者存活率提高了4% - 5%。3. 活体供体移植受者的移植肾存活率也有所改善。总体存活率从1988年的88%升至1991年的93%(p<0.003),不过1992年的结果表明92%可能是更合理的预期。约4%的升幅分布在各主要供体关系的受者中:HLA完全相同的同胞(3%);单倍型匹配的同胞(8%);以及父母(4%)。患者存活率提高了1%至3%。4. 配偶间移植以及远亲或其他非亲属供体间移植取得了出色的结果。284例配偶供体移植的1年和3年移植肾存活率分别为92%和85%。533例接受远亲或其他活体供体移植患者的相应结果为91%和84%。在每种情况下,结果均高于父母向子女的移植(尽管差异无统计学意义)。5. 预防性给予抗淋巴细胞抗体(抗淋巴细胞球蛋白/抗胸腺细胞球蛋白/OKT3)使首例尸体肾移植受者的移植肾存活率提高了多达4%。接受1个或2个HLA抗原错配肾脏的患者每年的移植肾存活率比接受5个或6个抗原错配的患者高2% - 10%。6. HLA配型使白人、黑人和亚洲人的移植肾存活率更高。在白人中,有大量配型良好的移植病例,无错配时3年移植肾存活率为84%,1个或2个、3个或4个、5个或6个错配时分别为75%、71%和67%。3年存活率的每次下降均具有显著性(p<0.001)。在黑人和亚洲人中,排名呈现类似趋势,尽管每个种族中配型良好的患者数量较少。(摘要截选至400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验